Brain

The following list provides a brief description of brain cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

 

F.I.G

Registered Title A prospective, multicentre trial evaluating the use of O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography (FET-PET) imaging in radiotherapy planning and clinical management of people with glioblastoma.
Purpose To investigate how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for GBM.
To determine the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.
Lay Summary  It is hoped that this new imaging approach with FET-PET scans will lead to more accurate assessment, and improve both treatment decisions and outcomes for patients with Glioblastoma. Currently FET-PET scans are not part of routine care for patients diagnosed with Gliobastoma. The use of FET-PET is experimental.
WA Trial Sites   Radiation Oncology  Ph. (08) 6383 3204
Links  Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

 

MoST 6

Registered Title  Single arm, open label, signal seeking, phase IIa trial of the activity of larotrectinib in patients with advanced NTRK1-3 positive tumours
Purpose The aim of MoST substudies 14 - 15 is to assess the clinical activity of larotrectinib in patients with advanced (rare) solid cancers harbouring NTRK 1-3 rearrangements/fusions into two groups:
Group 1: primary central nervous system (CNS) cancers
Group 2: non-CNS cancers.
Primary and secondary objectives are per framework with one substudy specific objective below.
Secondary objectives
Progression free survival at 6 months.
Tertiary objectives
1. To evaluate biomarkers that may correlate with clinical activity including response, resistance and tolerability
2. To determine the frequency of NTRK1-3 mutations in a population of advanced, adult-onset rare cancers
3. To determine the mechanism of resistance in patients who progress on larotrectinib
Lay Summary  N/A
WA Trial SItes  Ph. 08 6382 5513
 Links  Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

 

MAGMA

Registered Title A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma.
Purpose "This study aims to evaluate the use of temozolomide in different regimes for Glioblastoma. The trial is testing two changes to the usual schedule of treatment.

 

Lay Summary  It is hoped this research will help identify if starting temozolomide earlier than usual and/or continuing treatment with temozolomide for longer than usual will improve the outcomes of people with glioblastoma and assist development of future treatments."
WA Trial Sites  Medical Oncology Ph. (08) 6383 3000
 Links  Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

 

EX-TEM

Registered Title To determine if extended post-radiation temozolomide will improve survival outcomes in patients with newly diagnosed glioblastoma
 
 Purpose  The purpose of this study is to determine if an extended use of a chemotherapy medication (temozolomide) after radiation improves survival outcome in patients with newly diagnosed brain cancer (also called a glioblastoma).
 Lay Summary N/A
 WA Trial

Medical Oncology Ph. (08) 6383 3000

 Links  Australia New Zealand Clinical Trials Registry

Acknowledgements: Australia New Zealand Clinical Trials Registry

 

OUTRUN / TROG 17.02

Registered Title  Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (TROG 17.02 OUTRUN)
 
Purpose   The aim of this study is to compare the effects of Osimertinib alone versus SRS plus Osimertinib on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.
 Lay Summary  20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM study. Stereotactic radiosurgery (SRS) is one of the standard local treatment for patients with limited number of brain metastases. Currently, it is unclear whether adding SRS to Osimertinib will result in superior intracranial disease control in patients.  
 WA Trial

Radiation Oncology Ph. 08) 6383 3204

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

[Return to List of Clinical Trials]